We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PhoenixMD

News List

PhoenixMD Announces First Patient Dosed in Triple Negative Breast Cancer Trial americanpharmaceuticalreview
December 11, 2020
Phoenix Molecular Designs (PhoenixMD) announced the first patient has been dosed in their Phase 1b clinical trial of PMD-026.
Phoenix Molecular Designs Receives FDA Clearance to Begin PMD-026 Trial americanpharmaceuticalreview
September 24, 2019
Phoenix Molecular Designs (PhoenixMD) received clearance from the Food and Drug Administration (FDA) for PhoenixMD's Investigational New Drug (IND) application for its proprietary PMD-026.
Roche, PhoenixMD collaborate on diagnostic that may help identify triple-negative breast cancer patients who might benefit from RSK inhibitor PMD-026 firstwordpharma
January 17, 2019
In September, PhoenixMD announced that it raised $2.7 million to advance PMD-026 through investigational new drug (IND)-enabling studies and to develop a companion diagnostic to determine which patients have high levels of activated RSK2.